Gibraltar Capital Management Inc. Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

Gibraltar Capital Management Inc. raised its holdings in Pfizer Inc. (NYSE:PFE) by 2.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 20,307 shares of the biopharmaceutical company’s stock after acquiring an additional 571 shares during the quarter. Gibraltar Capital Management Inc.’s holdings in Pfizer were worth $585,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares during the last quarter. Invesco Ltd. boosted its position in shares of Pfizer by 30.9% during the 3rd quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock valued at $797,901,000 after acquiring an additional 5,678,004 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Pfizer by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after purchasing an additional 5,185,453 shares during the period. Bank of Nova Scotia grew its stake in shares of Pfizer by 219.4% in the 3rd quarter. Bank of Nova Scotia now owns 5,503,983 shares of the biopharmaceutical company’s stock valued at $182,567,000 after buying an additional 3,780,696 shares during the period. Finally, Van ECK Associates Corp lifted its holdings in Pfizer by 33.6% in the fourth quarter. Van ECK Associates Corp now owns 12,984,150 shares of the biopharmaceutical company’s stock valued at $373,813,000 after acquiring an additional 3,265,276 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Stock Down 0.1 %

NYSE:PFE traded down $0.03 during mid-day trading on Tuesday, hitting $25.61. The stock had a trading volume of 37,889,007 shares, compared to its average volume of 41,962,758. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The stock has a 50-day simple moving average of $26.88 and a two-hundred day simple moving average of $28.26. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $145.02 billion, a PE ratio of 71.14, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.14 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.56%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.